Developing High-Affinity Decoy Receptor Optimized for Multiple Myeloma and Diffuse Large B Cell Lymphoma Treatment
Y. R. Miao, K. Thakkar, C. Cenik, D. Jiang, K. Mizuno, C. Jia, G. C. Li, H. Zhao, A. Diep, J. Y. Xu, X. E. Zhang, T. T. C. Yang, M. Liedtke, P. Abidi, W.-s. Leung, , A. J. Giaccia
This paper develops an engineered sBCMA-Fc fusion protein with enhanced binding affinity to APRIL and BAFF, showing improved antitumor activity against multiple myeloma and diffuse large B cell lymphoma in preclinical models.
bioRxiv · May 3, 2021Cancer Biology